CA3130441A1 — Method for treatment of moderate to severe erythema symptoms in rosacea patients
Assigned to Sol Gel Technologies Ltd · Expires 2020-08-27 · 6y expired
What this patent protects
A regimen for the therapeutic treatment of moderate to severe erythema symptoms in rosacea patients, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w t…
USPTO Abstract
A regimen for the therapeutic treatment of moderate to severe erythema symptoms in rosacea patients, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 12 weeks, to achieve a percentage decrease of about 60% in a population exhibiting moderate to severe erythema symptoms when measured at about 12 weeks after initial treatment of the population with the pharmaceutical composition.
Drugs covered by this patent
- Benzamycin (BENZOYL PEROXIDE) · Mayne Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.